6505--VA GLA Pluvicto and Lutathera

NOTICE OF INTENT TO SOLE SOURCE This notice is being published in accordance with Federal Acquisition Regulation (FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. This is a notice of intent to award a sole source contract and is not a request for competitive quotes/proposals. The Department of Veterans Affairs, Network Contracting Office (NCO) 22, located at 4811 Airport Plaza Drive, Long Beach, CA is issuing this Notice of Intent (NOI) to inform industry contractors of the Government s intent to execute a Sole Source Delivery Order under FAR Part 8, specifically FAR Part 8.405-6(a)(1)(B), Only One Available Source.

The North American Industry Classification System (NAICS) for this requirement is 325412, Pharmaceutical Preparation Manufacturing. The Federal Supply Class (FSC) is 6505, Drugs and Biologicals. The Small Business Administration (SBA) size standard for this sector is 1,300 Employees.

The intended contractor is Novartis Pharmaceuticals Corporation located at 59 Route 10, East Handover, NJ 07936. Place of Performance is the VA Greater Los Angeles Healthcare System located at 11301 Wilshire Blvd, Los Angeles, CA 90073. VA Greater Los Angeles Nuclear Medicine Service intends to purchase Pluvicto (lutetium Lu-177 vipivotide tetraxetan 27 mCi/mL) and Lutathera (lutetium LU 177 Dotatate) in quantities listed below: NDC# Contract Description Qty UOM 00078-1217-61 36F79720D0180 Pluvicto (lutetium Lu-177 vipivotide tetraxetan 27 mCi/mL) 116 EA 69488-0003-01 36F79720D0180 Lutathera (lutetium LU 177 Dotatate) 13 EA VA Greater Los Angele Healthcare System Nuclear Medicine Service requires Pluvicto to treat advance prostate cancer and Lutathera to treat neuroendocrine tumor therapy.

Radiopharmaceuticals requested were awarded to Novartis Pharmaceuticals Corporations on 7/30/2020 under contract 36F79720D0180. If your firm provides the radiopharmaceutical therapy on GSA Federal Supply Schedule or any Federal Supply Schedule, please provide applicable contract number and identify which supply/service are applicable to that FSS contract, and the following additional information

1. A tailored capability statement indicating the firm s ability to provide a product and related services;
2. The respondents SAM UEI number, organization name, address, point of contact, and size and type of business (e.g., SDVOSB/VOSB, etc,) pursuant to the applicable NAICS code;
3. Information should be provided electronically in a Microsoft Word or Adobe PDF format.

Potential offerors must be a manufacturer or fully licensed, authorized distributor for the radiopharmaceutical items. Potential offerors must be FDA certified. This notice of intent is not a request for competitive quotes.

However, interested parties may identify their interest and capability to respond to the requirement and submit capability statement no later than 10:00 am., PT, Thursday November 1, 2026, to: Hestia Sim at [email on the source notice]. Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses received to this notice is solely within the discretion of the Government. If no written response is received within the closing date of this notice, a single source delivery order award will be made to Novartis Pharmaceuticals Corporation without any further notice.

This notice does not obligate the Government to award an agreement or otherwise pay for the information provided in response to this notice. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work.

Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. However, responses to this notice will not be considered adequate responses to a notice.